Ascendis Pharma A/S

NASDAQ

Market Cap.

12B

Avg. Volume

466.98K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Ascendis Pharma A/S

Ascendis Pharma A/S News

Ascendis Pharma A/S Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
ascendispharma.com

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S Earnings & Revenue

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

Ascendis Pharma A/S Financials

Table Compare

Compare ASND metrics with:

   

Earnings & Growth

ASND

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ASND

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ASND

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ASND

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Ascendis Pharma A/S Income

Ascendis Pharma A/S Balance Sheet

Ascendis Pharma A/S Cash Flow

Ascendis Pharma A/S Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Ascendis Pharma A/S Executives

NameRole
Mr. Flemming Steen JensenExecutive Vice President of Product Supply & Quality
Mr. Jan Moller MikkelsenPresident, Chief Executive Officer, Member of Executive Board & Executive Director
Mr. Scott T. SmithChief Financial Officer, Executive Vice President & Member of Executive Board
Ms. Pedersen Anni Lotte Kirstine SonderbjergExecutive Vice President, Chief Administrative Officer & Member of the Executive Board
Mr. Michael Wolff Jensen L.L.M.Executive Vice President, Chief Legal Officer & Member of the Executive Board
NameRoleGenderDate of BirthPay
Mr. Flemming Steen JensenExecutive Vice President of Product Supply & QualityMale1961

--

Mr. Jan Moller MikkelsenPresident, Chief Executive Officer, Member of Executive Board & Executive DirectorMale1960

--

Mr. Scott T. SmithChief Financial Officer, Executive Vice President & Member of Executive BoardMale1974

--

Ms. Pedersen Anni Lotte Kirstine SonderbjergExecutive Vice President, Chief Administrative Officer & Member of the Executive BoardFemale1961

--

Mr. Michael Wolff Jensen L.L.M.Executive Vice President, Chief Legal Officer & Member of the Executive BoardMale1971

--

Discover More

Streamlined Academy

Ascendis Pharma A/S

NASDAQ

Market Cap.

12B

Avg. Volume

466.98K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Ascendis Pharma A/S News

Ascendis Pharma A/S Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Ascendis Pharma A/S Earnings & Revenue

Ascendis Pharma A/S Income

Ascendis Pharma A/S Balance Sheet

Ascendis Pharma A/S Cash Flow

Ascendis Pharma A/S Financials Over Time

Ascendis Pharma A/S Executives

NameRole
Mr. Flemming Steen JensenExecutive Vice President of Product Supply & Quality
Mr. Jan Moller MikkelsenPresident, Chief Executive Officer, Member of Executive Board & Executive Director
Mr. Scott T. SmithChief Financial Officer, Executive Vice President & Member of Executive Board
Ms. Pedersen Anni Lotte Kirstine SonderbjergExecutive Vice President, Chief Administrative Officer & Member of the Executive Board
Mr. Michael Wolff Jensen L.L.M.Executive Vice President, Chief Legal Officer & Member of the Executive Board
NameRoleGenderDate of BirthPay
Mr. Flemming Steen JensenExecutive Vice President of Product Supply & QualityMale1961

--

Mr. Jan Moller MikkelsenPresident, Chief Executive Officer, Member of Executive Board & Executive DirectorMale1960

--

Mr. Scott T. SmithChief Financial Officer, Executive Vice President & Member of Executive BoardMale1974

--

Ms. Pedersen Anni Lotte Kirstine SonderbjergExecutive Vice President, Chief Administrative Officer & Member of the Executive BoardFemale1961

--

Mr. Michael Wolff Jensen L.L.M.Executive Vice President, Chief Legal Officer & Member of the Executive BoardMale1971

--

Ascendis Pharma A/S Insider Trades

No data available

DateNameRoleTransactionTypeShares

No data available

Streamlined Academy

Website screenshot
HealthcareBiotechnology
ascendispharma.com

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Ascendis Pharma A/S

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

Ascendis Pharma A/S Financials

Table Compare

Compare ASND metrics with:

   

Earnings & Growth

ASND

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ASND

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ASND

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ASND

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

The Secret to Analyzing Winning Stocks (Step-by-Step Examples Inside)